Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis

Gut

Volumn 69, Issue 1, 2020, Pages 92-102

  Lemoinne, Sara ^a,b   Kemgang, Astrid ^a,b   Ben Belkacem, Karima ^a,b   Straube, Marjolène ^a,b   Jegou, Sarah ^a,b   Corpechot, Christophe ^a,b   Chazouillères, Olivier ^a,b   Housset, Chantal ^a,b   Sokol, Harry ^a,b,c   Lemoinn, Sara ^a   Lionel, Arrivé ^d   Laurent, Beaugerie ^d   Anne, Bourrier ^d   Marine, Camus ^d   Najim, Chafai ^d   Édouard, Chambenois ^d   Ulriikka, Chaput ^d   Charlotte, Delattre ^d   Chloé, Martineau ^d   Laurence, Cholley Monnier ^d   Clotilde, Debove ^d   Xavier, Dray ^d   Jean François, Fléjou ^d   Guillaume, Le Gall ^d   Nadia, Hoyeau ^d   Julien, Kirchgesner ^d   Cecilia, Landman ^d   Jérémie, Levèvre ^d   Philippe, Marteau ^d   Isabelle, Nion Larmurier ^d   Violaine, Ozenne ^d   Yann, Parc ^d   Philippe, Seksik ^d   Harry, Sokol ^d   Magali, Svrcek ^d   more..

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c AGROPARISTECH   (France)

^d NONE

Author keywords

fungi; gut microbiota; inflammatory bowel disease; primary sclerosing cholangitis

Indexed keywords

AMINOSALICYLIC ACID; DNA 16S; INTERNAL TRANSCRIBED SPACER 2; STEROID; URSODEOXYCHOLIC ACID;

ADULT; ALTERNARIA; AMPLICON; ARTICLE; ASCOMYCETES; BASIDIOMYCETES; CANDIDA; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEBARYOMYCES; DISEASE DURATION; DISEASE SEVERITY; DNA SEQUENCE; DYSBIOSIS; EXOPHIALA; FEMALE; FILOBASIDIUM; FUSARIUM; HOST FUNGUS INTERACTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; KLUYVEROMYCES; MALE; MICROBIAL DIVERSITY; NONHUMAN; PENICILLIUM; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS; AGED; BACTERIUM; BACTERIUM IDENTIFICATION; BIODIVERSITY; CLASSIFICATION; FUNGUS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; SCLEROSING CHOLANGITIS; YOUNG ADULT;

ADULT; AGED; BACTERIA; BACTERIAL TYPING TECHNIQUES; BIODIVERSITY; CHOLANGITIS, SCLEROSING; DYSBIOSIS; FEMALE; FUNGI; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; YOUNG ADULT;

EID: 85064518124     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-317791     Document Type: Article

References (48)

1. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-55.
2. Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet 2013;382:1587-99.
3. Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975-84.
4. L i X, Shen J, Ran Z. Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease. Clin Immunol 2017;175:115-23.
5. Henriksen EK, Melum E, Karlsen TH. Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol 2014;30:310-9.
6. Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis-A comprehensive review. J Hepatol 2017;67:1298-323.
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med Overseas Ed 2002;347:417-29.
8. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-6.
9. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183-9.
10. R ossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 2015;9:342-8.
11. Kevans D, Tyler AD, Holm K, et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 2016;10:330-7.
12. T orres J, Bao X, Goel A, et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016;43:790-801.
13. Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016;65:1681-9.
14. Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 2017;23:4548-58.
15. I wasawa K, Suda W, Tsunoda T, et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 2017;66:1344-6.
16. Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017;66:611-9.
17. Quraishi MN, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 2017;66:386.1-8.
18. R ühlemann MC, Heinsen FA, Zenouzi R, et al. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 2017;66:753-4.
19. T orres J, Palmela C, Brito H, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J 2018;6:112-22.
20. Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 2017;127:2829-41.
21. Bajaj JS, Liu EJ, Kheradman R, et al. Fungal dysbiosis in cirrhosis. Gut 2018;67:1146-54.
22. Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut 2017;66:1039-48.
23. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 2003;132:473-6.
24. R udolph G, Gotthardt D, Klöters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009;51:149-55.
25. E uropean Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
26. C orpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970-9.
27. Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 2011;27:863-4.
28. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011;27:2957-63.
29. C aporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335-6.
30. Kõljalg U, Nilsson RH, Abarenkov K, et al. Towards a unified paradigm for sequence-based identification of fungi. Mol Ecol 2013;22:5271-7.
31. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79.
32. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94.
33. Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol 2013;13:175.
34. C hen YM, Liu Y, Zhou RF, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep 2016;6:19076.
35. Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015;5:8096.
36. Hiippala K, Jouhten H, Ronkainen A, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients 2018;10:988.
37. Hirano A, Umeno J, Okamoto Y, et al. Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol 2018:1590-7.
38. Ye JZ, Li YT, Wu WR, et al. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. World J Gastroenterol 2018;24:2468-81.
39. Udayappan S, Manneras-Holm L, Chaplin-Scott A, et al. Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes 2016;2:16009.
40. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-6.
41. Kollerov VV, Lobastova TG, Monti D, et al. Deoxycholic acid transformations catalyzed by selected filamentous fungi. Steroids 2016;107:20-9.
42. Van den Bossche L, Hindryckx P, Devisscher L, et al. Ursodeoxycholic acid and its taurine-or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol 2017;83.
43. T ang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018;67:534-41.
44. Vasquez A, Zavasky D, Chow NA, et al. Management of an outbreak of exophiala dermatitidis bloodstream infections at an outpatient oncology clinic. Clin Infect Dis 2018;66:959-62.
45. Oztas E, Odemis B, Kekilli M, et al. Systemic phaeohyphomycosis resembling primary sclerosing cholangitis caused by Exophiala dermatitidis. J Med Microbiol 2009;58:1243-6.
46. Hong KH, Kim JW, Jang SJ, et al. Liver cirrhosis caused by Exophiala dermatitidis. J Med Microbiol 2009;58:674-7.
47. I wasawa K, Suda W, Tsunoda T, et al. Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker. Sci Rep 2018;8:5480.
48. G rander C, Adolph TE, Wieser V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 2018;67:891-901.